Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.

doi:10.1182/blood.2021011103

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.

Blood - 19 Aug 2021

Itzykson Raphael, Fournier Elise, Berthon Céline, Röllig Christoph, Braun Thorsten, Marceau-Renaut Alice, Pautas Cécile, Nibourel Olivier, Lemasle Emilie, Micol Jean-Baptiste, Adès Lionel, Lebon Delphine, Malfuson Jean-Valère, Gastaud Lauris, Goursaud Laure, Raffoux Emmanuel, Wattebled Kevin-James, Rousselot Philippe, Thomas Xavier, Chantepie Sylvain, Cluzeau Thomas, Serve Hubert, Boissel Nicolas, Terré Christine, Celli-Lebras Karine, Preudhomme Claude, Thiede Christian, Dombret Hervé, Gardin Claude, Duployez Nicolas

Abstract excerpt

To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) ≥60 years of age treated with 7 + 3, we sequenced 37 genes in 471 patients from the ALFA1200 (Acute Leukemia French Association) study (median age, 68 years). Mutation patterns and OS differed between the 84 patients with poor-risk cytogenetics and the 387 patients with good (n = 13),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Cytogenetics

Share to Disease-Free Survival

Share to Follow-Up Studies

Share to Leukemia, Myeloid, Acute

Share to Neoplasm Proteins

Share to Survival Rate

Source

Open in PubMed

Identifiers

PMID: 34410352
DOI: 10.1182/blood.2021011103

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.PMID 34410352Read ↗

A precision medicine classification for treatment of acute myeloid leukemia in older patients.Semantic proximity Read ↗

A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries.Semantic proximity Read ↗

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older.Semantic proximity Read ↗

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology).Semantic proximity Read ↗

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.Semantic proximity Read ↗

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.Semantic proximity Read ↗

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.Semantic proximity Read ↗

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.Semantic proximity Read ↗

How to improve AML outcomes?Semantic proximity Read ↗

Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.Semantic proximity Read ↗

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study.Semantic proximity Read ↗

Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.